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PRM209  
HOW ARE CENTRES INCLUDED IN RANDOMISED CONTROLLED TRIALS WITH 
PARALLEL ECONOMIC EVALUATIONS IN THE UK?  
Gheorghe A, Roberts TE, Fletcher BR, Calvert M 
University of Birmingham, Birmingham, UK  
OBJECTIVES: The sample of centres participating in randomised controlled trials 
(RCTs) may affect the generalisability of economic evaluation results if it is 
biased, but there is limited evidence on how trialists currently include centres in 
RCTs. Our aim was to investigate the reported rationales for centre selection in 
RCTs with parallel economic evaluations in the UK. METHODS: We 
systematically reviewed and meta-summarised centre selection information in 
full-length protocols of RCTs with parallel economic evaluations funded by the 
UK National Institute of Health Research – Health Technology Assessment 
programme (NIHR-HTA) and initiated between January 2005 and January 2012. 
Free text information on centre selection was extracted, abstracted and 
categorised; effect sizes (%) were calculated for the emerging categories as a 
measure of prevalence relative to the number of included studies. RESULTS: Of 
365 reviewed studies, 129 trial protocols were included in the systematic review 
with a total target sample size of 317,000 participants. The meta-summary 
identified 53 centre selection considerations, grouped under three categories: 
diversity and representativeness, centre characteristics and trial participation. A 
total of 78 (60%) protocols provided a rationale for centre selection. A total of 31 
(24%) protocols explicitly considered representativeness, for example in terms of 
the target population (11%) and delivered services (12%). Fifty-seven (44%) 
protocols required particular centre characteristics, such as size (17%) and 
research experience (15%). Thirty-seven (29%) protocols envisaged 
considerations that would ensure successful trial participation, such as the 
willingness to participate (7%) and ensuring recruitment (13%). CONCLUSIONS: 
The rationale for centre selection in RCTs with parallel economic evaluations is 
currently underreported in trial protocols. Centres are primarily enrolled on 
pragmatic grounds and less so with a view to ensuring generalisability. There are 
little reasons to believe that economic results from RCTs are informed by a 
representative sample of centres, thus questioning the representativeness of 
their findings.  
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RECRUITING PATIENTS WITH A RARE BLOOD DISORDER AND THEIR 
CAREGIVERS THROUGH SOCIAL MEDIA  
DiBenedetti DB1, Coles TM1, Sharma T2 
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novo Nordisk A/S, Søborg, Denmark  
OBJECTIVES: Recruiting research participants with experiences relevant to rare 
diseases (patients and caregivers) remains a constant challenge. Researchers often 
rely on patient advocacy or support groups as well as clinician referrals, which each 
present unique recruitment issues. Social media sites, such as Facebook, can 
potentially be helpful in recruiting patients for many study types, particularly those 
involving hard-to-reach populations. However, little is known about the value of 
social media in recruiting populations with rare medical conditions. In this study, 
Facebook was used to recruit adult patients and parents of children with 
hemophilia A for participation in a Web-based survey. METHODS: A cross-sectional 
study was developed to better understand patient and caregiver experiences and 
behaviors associated with treatments for hemophilia A. Members of three local or 
national blood disorder organizations in the United States and Canada were invited 
to complete a Web-based survey via postings on each organizations' Web site 
and/or e-mail invitations sent to each organizations' member lists. Additionally, 
two organizations posted advertisements about the study on their respective 
Facebook pages. A nominal donation was made to each organization for their 
assistance in study recruitment. RESULTS: Of the 145 individuals who responded to 
survey invitations, 101 (70%) completed the survey questionnaire. More than half 
(58%) of the completed questionnaires were from respondents recruited through 
Facebook who were a mean age of 35.8 years (SD = 8.3), similar to those recruited 
through more standard methods. The organization that did not post a study 
advertisement on Facebook recruited the fewest participants (only 13% of the total 
respondents). CONCLUSIONS: This real-world study emphasizes the assistance and 
value of social media in study recruitment. Use of social media in recruiting can be 
an efficient means of reaching large numbers of potential respondents.  
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THE EFFECTS OF EXCLUDING TREATMENTS FROM NETWORK META-ANALYSIS  
Mills E1, Kanters S2, Thorlund K1 
1Stanford University, Palo Alto, CA, USA, 2University of British Columbia, Vancouver, BC, 
Canada  
OBJECTIVES: To investigate the effect of omitting treatments from network 
meta-analyses on overall treatment effects and treatment rankings. METHODS: 
We selected published network meta-analyses that met the following criteria: 
compared t≥5 treatments, had ≥2 loops, ≥2tstudies and set to determine 
treatment superiority. If multiple published analyses considered the same 
treatments (e.g. multiple networks pertaining to COPD drugs), the larger network 
was selected. We defined a node’s connectivity as its number of edges. Each 
network was analyzed systematically with the removal of one node at a time. 
Nodes that were in ≥50% of studies were not removed. Impact of node exclusion 
was measured using the relative change in treatment effect estimates, changes 
in the top-three ranked treatments, and changes in probabilities of being the 
best treatment. Relative changes in effect size were expressed as fold-deviations. 
For each network with excluded node(s), we measured the maximum and 
geometric mean of fold-changes. RESULTS: In total, 19 networks were selected 
for analysis. Approximately half the networks had average fold-change larger 
than 1.10 (greater than 10% relative change in treatment effects). Approximately 
half of the networks also had changes in the top three ranks and substantial 
changes in treatment rank probabilities. Within these networks, the maximum 
fold-change was generally larger than 1.25. In networks with no changes in top-
three ranked treatments, the ‘best’ treatment mostly had probability ≥70% of 
being the best. Two features were consistent across the nodes leading to the 
largest change in probabilities and effects: they were among the most connected 
nodes and tended to have a 0% probability of being the best treatment. 
CONCLUSIONS: Network meta-analytic methods are still in their infancy. Our 
results suggest that failing to include one or more treatments within a network 
can lead to important changes in conclusions reached.  
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USING AN ONLINE DATA ANALYTIC TOOL TO INFORM STUDY DESIGNS FOR 
CHRONIC DISEASE POPULATIONS: A CASE STUDY WITH CLL  
Foley K1, Hansen LG2 
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Northwood, NH, USA  
OBJECTIVES: Chronic lymphocytic leukemia (CLL) accounts for almost 40% of all 
leukemias. Current treatments have high rates of adverse events requiring 
hospitalization. With promising treatments on the horizon, the need for well-
designed studies of treatment patterns and adverse events will increase. 
Designing studies can be challenging given the long-term nature of CLL. This 
study uses an online analytic tool to explore the necessary observation period to 
accurately assess treatment and hospitalization rates. METHODS: Using the 
Treatment Pathways tool and data from an 8-year oncology subset of the 2004 – 
2012 MarketScan®databases, we identified patients with two plus claims for CLL, 
one year prior enrollment, no prior treatment. Four follow-up groups were 
assessed: 1, 2, 3, and 4 years of continuous enrollment (CE). For each CE, we 
identified patients treated with bendamustine (B), or fludarabine, rituximab, 
and/or cyclophosphamide (F/R/C). Treatment and hospitalization rates and the 
time between diagnosis, treatment, and hospitalization were calculated. 
RESULTS: A total of 4886 patients met all inclusion criteria; 3348 had 1 year, 2201 
had 2 years, 1451 had 3 years, and 874 had 4 years CE. Bendamustine use 
increased from 4% among those with 1 year CE to 5% for all other CE groups. 
F/R/C use increased from 21% among those with 1 year to 27% among those with 
4 years CE. Hospitalization rates increased from 41% to 49% for bendamustine, 
and 38% to 44% for F/C/R from 1 year to 4 years CE. Among those with 4 yrs CE, 
median time to first treatment was 4.3 years for bendamustine, 1.4 years for 
F/C/R; median time to first hospitalization was 96 and 365 days, respectively. 
CONCLUSIONS: This study used an online tool to quickly assess the impact of 
various CE criteria. The data demonstrate how shorter CE underestimates 
treatment, related hospitalizations, and overall burden of illness in a chronic 
population.  
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USING REAL-WORLD CLAIMS DATA FOR PLANNING ONCOLOGY CLINICAL 
TRIALS  
Foley KA1, Hansen LG2 
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Northwood, NH, USA  
OBJECTIVES: To understand the value of quickly estimating the impact of certain 
inclusion/exclusion criteria on a potential clinical trial population using real-
world administrative data. METHODS: Using the Treatment Pathways tool and 
data from an 8-year oncology subset of the 2004 – 2012 MarketScan®databases, 
we identified patients with castrate-resistant prostate cancer (CRPC) with at least 
six months of history. From these patients, we identified cohorts with definitive 
exclusions (brain metastasis or other primary cancer) and time-dependent 
exclusions (based on radiation or treatments). Seven of 12 exclusion criteria were 
identifiable within the claims database. RESULTS: Inclusion criteria identified 
2,329 patients with CRPC based on two prostate cancer diagnoses, medical or 
surgical castration and receipt of docetaxel. Of them, 1370 (59%) had 6 months of 
follow-up data for evaluation of exclusion criteria. Among the 1370 patients, 248 
(18%) met none of the exclusion criteria, while 482 patients (35%) had brain 
metastasis and/or other cancers. The remaining 640 (47%) had at least one time-
dependent exclusion, including 534 receiving corticosteroids, 136 receiving 
androgen receptor and reductase inhibitors, 86 receiving radiation and 31 with 
ketoconazole. These patients could be trial-eligible depending on the timing of 
treatment cessation and trial recruitment. CONCLUSIONS: This study 
demonstrates a method to understand the impact of specific inclusion/exclusion 
criteria on a potential clinical trial population in just a few hours using an online 
pathway creation tool and administrative data representing millions of patients. 
Using this method, trial planners can evaluate different scenarios to quickly and 
easily determine estimated attrition rates helping them to maximize potential 
recruitment success. Limitations exist due to the timing of exclusions and data 
on lab results included in the exclusion criteria that were unavailable in this 
subset of claims data.  
 
PRM214  
USE OF A NOVEL ADJUNCTIVE CLINICAL TRIAL DESIGN TO EXAMINE 
EFFICACY, SAFETY OF ARMODAFINIL FOR THE TREATMENT OF BIPOLAR I 
DEPRESSION  
Calabrese JR1, Ketter TA2, Yang R3, Frye MA4 
1University Hospitals Case Medical Center, Cleveland, OH, USA, 2Stanford University School of 
Medicine, Stanford, CA, USA, 3Teva Pharmaceutical Industries Ltd., Frazer, PA, USA, 4Mayo 
Clinic, Rochester, MN, USA  
OBJECTIVES: Patients in randomized, controlled trials of bipolar depression are 
generally not representative of a clinical population. This study attempted to 
examine a large sample of patients more representative of patients seen in 
clinical practice. This report presents baseline patient characteristics from a 
